Nkarta Q3 2026 net loss widens 53% to $33.33 million

Bitget2026/11/05 23:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nkarta's third-quarter 2026 net loss widened 53% year over year to $33.33 million.
Research and development expenses jumped 46% year over year to $29.46 million.
Cash, cash equivalents, restricted cash and investments totaled $216 million at September 30; the operating plan is funded into 2029.
Initial NKX019 clinical data in myositis and systemic sclerosis will be presented at ACR Convergence 2026; outpatient dosing is underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051634PRIMZONEFULLFEED9871798) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nkarta Q3 2026 net loss widens 53% to $33.33 million

You may also like

Crypto prices